Axela Biosciences, Inc. (merged from NanoBiotec/PicoImmune/EmerTher) offers ultra-sensitive, multiplex, and reliable bioassay services for real-time monitoring of protein and gene changes in minute samples from cells, animals, and patients, thereby accelerating the discovery and development of novel therapeutics.

Our team possesses extensive expertise in drug discovery and unparalleled proficiency in bioanalytical, cytometric, genomic, and proteomic techniques. We harness the power of ultra-sensitive femto-scale and multiplex immunoassays as well as microarray technologies to assess drug efficacy and elucidate the underlying mechanisms of drugs and diseases.

With training from leading institutions such as MIT, NIH, MSKCC, Rutgers, NYU, and Duke, and experience at leading biopharma companies including Novartis, Sanofi, Merck, BMS/Celgene, Boehringer Ingelheim and Regeneron, our scientists offer deep biopharma industry knowledge and technical proficiency.

We have established a state-of-the-art infrastructure equipped with cutting-edge technologies and advanced instruments. Our suite of sophisticated platforms enables highly sensitive bioanalysis and drug screening using minimal sample sizes, thereby allowing us to meet diverse assay performance requirements. Our dedicated scientists possess extensive hands-on experience and training in utilizing these technologies and instruments, diligently adhering to well-validated protocols for swift and accurate processing and analysis of samples.